A double-blind, placebo-controlled study of the impact of prophylactic treatment with Galantamine 8mg of cognitive impairment during an electroconvulsive therapy (ECT) in patients with major depressive disorder (MDD).

CUB Hospital Erasme0 个研究点开始时间: 2015年4月21日最近更新: 2016年8月16日

试验速览

暂无简介。

•The subjects enrolled in the study will be major patients (>or= 18year) with major depressive disorder diagnosed according to DSM-IV, receiving electroconvulsive therapy.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 20
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 14

•Exclusion criteria are refusing to participate, lack of knowledge of French or an inability to respond to a type evaluation ACE-r (illiteracy, etc.), patients Patient who are forbiden to use the treatment because of disease such as heartburn, insufficient liver or kidney, COPD or active asthma, symptomatic urinary retention, bradycardia defined as heart rate less than 60 / min or block or QTc prolongation in ECG.
•The patient with schizoaffective disorder, defined according to DSM-IV-TR will also be excluded.
•Pregnant patients or patients without contraception during the therapy will not be included in the trial.
•We will exclude patients with deterioration of memory before the treatment. That is to say, all the patients with MMSE less than 25. If this score is between 25 and 30, we will select patients over 82 in the ACE-r with a maximum score of obligation question Q5 and Q23 of the CEA to ensure the encoding capacity and a good recovery information before ECT.

发起方

CUB Hospital Erasme